Treatment outcomes with hypofractionated high-dose radiation therapy for prostate cancer

Viani, Gustavo Arruda; Rossi, Bruno Tiago; Suguikawa, Elton; Zuliani, Gisele; Stefano, Eduardo Jose

doi:10.1016/j.rpor.2015.12.003

Cited by 2 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An estimated 17,000 patients are treated annually in the UK with radical radiotherapy (RT) for pelvic cancer [ 1 ]. New treatment approaches such as intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), fractionated delivery [ 2 ] and concomitant chemoradiotherapy (chemoradiotherapy (CRT)) have changed the subjective toxicity profile of radiotherapy (RT). Patients survive longer but suffer acute and long-term pelvic-related AE.…”

Section: Introductionmentioning

confidence: 99%

eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy

Holch

Pini

Henry

et al. 2018

Pilot Feasibility Stud

View full text Add to dashboard Cite

BackgroundAn estimated 17,000 patients are treated annually in the UK with radical radiotherapy (RT) for pelvic cancer. New treatment approaches in RT have increased survivorship and changed the subjective toxicity profile for patients who experience acute and long-term pelvic-related adverse events (AE). Multi-disciplinary follow-up creates difficulty for monitoring and responding to these events during treatment and beyond. Originally developed for use in systemic oncology therapy eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) is an online system for patients to report AEs from home. eRAPID enables patient data to be integrated into the electronic patient records for use in clinical practice, provides patient management advice for mild and moderate AE and advice to contact the hospital for severe AE. The system has now been developed for pelvic RT patients, and we aim to test the intervention in a pilot study with staff and patients to inform a future randomised controlled trial (RCT).MethodsEligible patients are those attending St James’s University hospital cancer centre and The Christie Hospital Manchester undergoing pelvic radiotherapy+/−chemotherapy/hormonotherapy for prostate, lower gastrointestinal and gynaecological cancers. A prospective 1:1 randomised (intervention or usual care) parallel group design with repeated measures and mixed methods will be employed. We aim to recruit 168 patients following recommendations for sample size estimates for pilot studies. Participants using eRAPID will report AE (at least weekly) from home weekly for 6 weeks and 6 weeks post-treatment (12-week total) then at 18 and 24 weeks. Hospital staff will review eRAPID reports and use information during consultations. Notifications will be sent to the relevant clinical team when severe symptoms are reported. We will measure patient-reported outcomes using validated questionnaires (Functional Assessment in Cancer Therapy Scale-General (FACT-G), European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC-QLQ-C30), process of care impact (hospital records of patient contacts and admissions) and economic variables (EQ5D-5L, patient use of resources)). Staff and patient experiences will be explored via semi-structured interviews.DiscussionThe objectives are to establish feasibility, recruitment, integrity of the system and attrition rates, determine effect sizes and aid selection of the primary outcome measure for a future RCT. We will also refine the intervention by exploring staff and patient views. The overall goal of this complex intervention is to improve the safe delivery of cancer treatments, enhance patient care and standardise documentation of AE within the clinical datasets.Trial registrationClinicalTrials.gov NCT02747264.Electronic supplementary materialThe online version of this article (10.1186/s40814-018-0304-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy

Holch

Pini

Henry

et al. 2018

Pilot Feasibility Stud

View full text Add to dashboard Cite

show abstract

“…Prostate cancer (PC) is the most common male cancer and radical radiotherapy (RRT) is a key treatment option available for localised and locally advanced disease 1 . Recent advances such as intensity-modulated radiation therapy, fractionated delivery regimens and volumetric modulated arc therapy 2 , 3 aim to reduce toxicity. However, both late and acute symptoms and side effects can still occur and impact on quality of life (QOL) 4 …”

Section: Introductionmentioning

confidence: 99%

“…modulated arc therapy 2,3 aim to reduce toxicity. However, both late and acute symptoms and side effects can still occur and impact on quality of life (QOL).…”

mentioning

confidence: 99%

Assessing the information and support needs of radical prostate cancer patients and acceptability of a group-based treatment review: a questionnaire and qualitative interview study

Chauhan

Holch²,

Holborn³

2018

J Radiother Pract

View full text Add to dashboard Cite

AimsCurrent literature suggests the information and support needs of oncology patients undergoing radical radiotherapy to the prostate often remain unmet and can impact quality of life. We aimed to explore the effectiveness of delivery and opportunities for service improvement, including a group based treatment review. Methods:Sixty prostate patients completing radical radiotherapy (mean age 70, range 47-79) in a UK cancer-centre completed a self-designed questionnaire assessing information and support.. To explore views on a group-based-treatment-review, 11% took part in a semi-structured interview. Descriptive data were computed and interviews transcribed and analysed thematically. Results:Eighty-seven percent were satisfied with information and support when delivered by radiographers. However, 26% were only 'sometimes' able to complete bladder-filling, suggesting information regarding treatment delays would improve this. 49% preferred both Doctor and Urology nurse reviews whereas 26% preferred nurse only. 70% stated their 'concerns were always addressed' by a nurse and 49% by a Doctor. Interviews revealed that a group review was generally acceptable with peer support an influencing factor. Findings:Overall patients felt their needs were being met. Suggestions for improvement (more information on preparation, side effects and delays) will be implemented locally. Future work will explore the feasibility of group reviews in patients undergoing radical radiotherapy to the prostate. Financial supportThis research received no specific grant from any funding agency, commercial or not-for-profit sectors.

show abstract

Treatment outcomes with hypofractionated high-dose radiation therapy for prostate cancer

Abstract: a b s t r a c tAim: To report the treatment results of a retrospective cohort of prostate cancer patients treated with Hypo-RT with a high equivalent biological effective dose (BED).Background: Hypofractionated radiotherapy (Hypo-RT) has gained popularity and interest in

Cited by 2 publications

References 17 publications

eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy

eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy

Assessing the information and support needs of radical prostate cancer patients and acceptability of a group-based treatment review: a questionnaire and qualitative interview study

Contact Info

Product

Resources

About